Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Mild traumatic brain injury (mTBI) is one of the most frequent emergencies in the elderly population. Despite most mTBI are managed with cranial computed tomography (CT), only 10% of CTs show lesions, determining CT overuse. The use of serum glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) have shown potential for ruling out the need for cranial CT. However evidence on biomarker use in mild TBI were not based on studies that included aged participants and patients with comorbidities for which biomarker levels could vary. This is why there is a need for a prospective study that assesses the predictive performance of these two biomarkers in the elderly population, both in elderly patients suffering mild TBI and in a reference population, including patients and participants with and without comorbidities.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
BRAINI2-ELDERLY DIAGNOSTIC & PROGNOSTIC:
BRAINI2-ELDERLY REFERENCE:
Exclusion criteria
BRAINI2-ELDERLY DIAGNOSTIC & PROGNOSTIC:
BRAINI2-ELDERLY REFERENCE:
2,850 participants in 2 patient groups
Loading...
Central trial contact
Alfonso Lagares Gómez-Abascal, MD, PhD; Javier De la Cruz, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal